This concept drove the initial development of poly (ADP-ribose) polymerase (PARP) inhibitors in the seminal phase I study of the PARP inhibitor olaparib in patients with advanced ovarian cancer and germline BRCA mutations [5]. Here, PARP1 is linked to ovarian cancer.